On March 31, 2022 Canthera Discovery reported that its predecessor, Cancer Therapeutics CRC, received the Cooperative Research Australia (CRA) Excellence in Innovation Award for Research Commercialisation at an award ceremony at Parliament House in Canberra on Thursday night (Press release, Canthera Discovery, MAR 31, 2022, View Source [SID1234611332]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cancer Therapeutics CRC, ran for 13 years (2007-2020) and was recognised for landing deals in ground-breaking cancer therapies with pharma giants for a headline value of close to A$1.4bn. It has 7 licensed programs in active development, including two currently in clinical trials.
"The CRC Program funded Cancer Therapeutics CRC with $71m over 13 years. In potentially returning some ten times that investment and counting in licensing deals, Cancer Therapeutics CRC and Canthera Discovery have been a shining example of the strength of the CRC Program in bridging the gap between domestic world class research and innovation, and global commercialisation," CRA CEO Jane O’Dwyer said.
"Cooperative Research Australia is delighted to present Canthera Discovery and Cancer Therapeutics CRC with the Award for Research Commercialisation," she said.
Brendon Monahan, Chief Scientific Officer, Canthera Discovery
Upon receiving the award, Brendon Monahan, Canthera Discovery Chief Scientific Officer commented, "Drug discovery requires a multi-disciplinary approach and collaboration is at the centre of everything we do. We would like to thank and acknowledge our Research Partners: WEHI, CSIRO, Monash University, Griffith University, Children’s Cancer Institute, and the Peter MacCallum Cancer Centre. Our CRC commercialisation partners SYNthesis Research and Oncology One. And all of our CRC participants."
"It is no secret that what has driven the success of Cancer Therapeutics CRC and now Canthera, is its people. The KAT6 project alone, which entered clinical trials in 2020, involved over 100 people, across 16 organisations, 10 research laboratories, and 11 different general fields combining science, business, and data management. We thank everyone, past and present, who have contributed expertise, creativity, and passion to our organisation and projects."